Study Summary
This is a single-center, open-label and pragmatic clinical trial to evaluate the primary efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19) with concurrent BTK inhibitor in patients with relapsed or refractory B cell lymphoma
Want to learn more about this trial?
Request More InfoInterventions
BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 CellsDRUG
BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Fludarabine-based chemotherapy + CAR-T-CD19 CellsDRUG
Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Union Hospital, Huazhong University of Science and Technology | Wuhan | Hubei | China |